Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $3.5 million.

  • NovaBay Pharmaceuticals' Liabilities and Shareholders Equity fell 1005.93% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.7 million, marking a year-over-year increase of 675.89%. This contributed to the annual value of $3.4 million for FY2024, which is 6210.98% down from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $3.5 million for Q3 2025, which was down 1005.93% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $24.8 million in Q1 2022 and a low of $3.4 million during Q4 2024
  • Its 5-year average for Liabilities and Shareholders Equity is $12.6 million, with a median of $12.9 million in 2023.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 7548.1% in 2024 and then surged by 8428.22% in 2025.
  • NovaBay Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $24.0 million in 2021, then crashed by 31.61% to $16.4 million in 2022, then plummeted by 44.91% to $9.0 million in 2023, then tumbled by 62.11% to $3.4 million in 2024, then grew by 1.87% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $6.9 million for Q2 2025, and $9.9 million during Q1 2025.